Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Aurora is trying to leave the worst cannabis-stock habits behind: Q3 FY2026 medical cannabis revenue set a record, management is exiting weaker Canadian consumer lanes, and the balance sheet has cash. The catch is that IFRS losses, Bevo restructuring, internal
OpenPhilip Morris generated $40.6 billion of 2025 revenue and $12.2 billion of operating cash flow, but the investment case depends on whether smoke-free growth, pricing, regulation and leverage can keep offsetting the structural decline and social risk of cigaret
OpenHershey reported FY2025 revenue of $11.7 billion, gross profit of $3.9 billion, operating income of $1.4 billion and Q1 2026 revenue of $3.1 billion. The thesis depends on cocoa-cost inflation, pricing power, brand demand, inventory control, cash conversion an
Open20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAgencia Comercial Spirits Ltd came public as a Taiwan whisky importer, then disclosed a 2026 AI infrastructure pivot with a non-binding US$120M server LOI, a US$14.55M PIPE, Indonesian power commitments and a five-year services agreement that may represent up
OpenAdvanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
OpenAditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenAcme United looks like a sleepy tools business until the filing mix shows first aid at roughly two-thirds of sales, a new My Medic deal, tariff pain, rising debt, and a customer-concentration test.
OpenAclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reim
OpenAbbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.
OpenOfficial-source baseline for Ambev using SEC submissions, SEC company facts, the FY2025 Form 20-F, Q1 2026 Form 6-K results materials, and official peer/controller filing context.
OpenAlbertsons has the scale, loyalty data, Own Brands, and cash flow to rebuild a standalone grocery thesis after the failed Kroger deal. The tension is whether low-margin retail, pharmacy headwinds, labor costs, debt, opioid charges, and capital returns leave en
OpenAgilent's CrossLab mix and cash generation point to a durable lab-workflow franchise, but the open question is whether service and consumables strength can outrun instrument-cycle volatility.
Open